85-2062-45 VEGF 165, Recombinant, Human, 165aa (VEGFA, Vascular Endothelial Growth Factor A, VEGF-A, Vascular Permeability Factor, VPF, VEGF) 20ug 207440
特徴
- Human vascular endothelial growth factor (VEGF 165) is produced as a homodimer. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. VEGF 165 is a specific mitogen for vascular endothelial cells and a strong angiogenic factor in vivo. In addition to its action as a mitogen it is a potent vascular permeability factor (VPF) in vivo. It is also a chemoattractant molecule for monocytes and endothelial cells. It induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels.
- Recombinant protein surrounding amino acid 165 from human VEGF 165, expressed in E. coli.
- Molecular Weight:~38.2kD
- Biological Activity:The ED50 for stimulation of cell proliferation in human umbilical vein endothelial cells by VEGF 165 has been determined to be in the range of 1-5ng/ml.
- Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months after receipt at -20°C. Reconstitute with 50mM acetic acid. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
仕様
- Size:20ug
- Source Antigen:Recombinant, E. coli
- Grade:Highly Purified
- Purity:≥95% (SDS-PAGE). Endotoxin: <0.1ng/ug
- Form:Supplied as a lyophilized powder. Reconstitute with 50mM acetic acid to a concentration ~50ug/ml.
- Molecular Weight Non Ab:38.2
- Swiss Prot Number:P15692
- EU Commodity Code:30021019
- この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
- 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
- 【試薬に関するお問合せ】
- アズワン株式会社 試薬・プロセス材料グループ
- TEL:06-6447-8641
- FAX:06-6447-8642
- E-mail:[email protected]
商品のバリエーション (サイズ違い・スペック違い・オプション品など)
よくあるご質問(FAQ)
掲載カタログ情報
| 掲載カタログ名 | 掲載ページ |
|---|





